Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the …
GYH Lip, X Pan, S Kamble, H Kawabata… - … journal of clinical …, 2016 - Wiley Online Library
Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
GYH Lip, A Keshishian, S Kamble… - Thrombosis and …, 2016 - thieme-connect.com
In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …
[HTML][HTML] Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
PG Tepper, J Mardekian, C Masseria, H Phatak… - PloS one, 2018 - journals.plos.org
Limited real-world data are available regarding the comparative safety of non-vitamin K
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …
antagonist oral anticoagulants (NOACs). The objective of this retrospective claims …
Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation
G Adeboyeje, G Sylwestrzak, JJ Barron, J White… - Journal of managed …, 2017 - jmcp.org
BACKGROUND: The use of non-vitamin K oral anticoagulants (NOACs) has increased
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
steadily following marketing approval; however, their relative safety in nonvalvular atrial …
Major bleeding complications and persistence with oral anticoagulation in non‐valvular atrial fibrillation: contemporary findings in real‐life Danish patients
M Lamberts, L Staerk, JB Olesen… - Journal of the …, 2017 - Am Heart Assoc
Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity …
S Kohsaka, T Murata, N Izumi, J Katada… - … medical research and …, 2017 - Taylor & Francis
Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …
[HTML][HTML] Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of …
Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban …
A Amin, A Keshishian, J Trocio, O Dina… - … medical research and …, 2017 - Taylor & Francis
Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
NW Andersson, H Svanström, M Lund… - International Journal of …, 2018 - Elsevier
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis
S Deitelzweig, C Farmer, X Luo, X Li, L Vo… - Current Medical …, 2018 - Taylor & Francis
Objective: To conduct a systematic literature review (SLR) and network meta-analysis (NMA)
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …
of real-world studies comparing major bleeding risk among patients with non-valvular atrial …